Sindrom Neuroleptik Maligna (SNM)

01Pathophysiology

NMS is a life-threatening idiosyncratic reaction caused by an abrupt and sustained blockade of dopamine D2 receptors in the central nervous system. The two principal anatomic targets are the hypothalamus and the nigrostriatal pathway (basal ganglia), and understanding what each contributes to the clinical picture is the key to answering vignettes correctly.

Hypothalamic D2 blockade disrupts the body's thermoregulatory set point. The hypothalamus normally modulates heat dissipation through sweating, vasodilation, and behavioral responses. When dopamine signaling is abruptly removed, the thermostat effectively "breaks," producing uncontrolled hyperthermia. This is compounded by the heat generated from sustained skeletal muscle contraction.

Nigrostriatal D2 blockade removes the inhibitory influence dopamine normally exerts on muscle tone. The result is diffuse, continuous skeletal muscle rigidity described classically as "lead-pipe" in character. This rigidity is distinct from the cogwheel rigidity of Parkinson disease because it is constant and non-velocity-dependent. The sustained contraction of large muscle groups causes rhabdomyolysis, which explains the dramatically elevated CK, the myoglobinuria, and the risk of acute kidney injury from myoglobin precipitation in renal tubules.

Autonomic instability arises from dysfunction of central and peripheral dopaminergic and sympathetic pathways. This manifests as tachycardia, labile or elevated blood pressure, diaphoresis, and tachypnea. The combination of sympathetic overdrive and impaired thermoregulation creates a dangerous feed-forward loop of rising temperature and worsening rigidity.

Altered mental status ranges from agitation and confusion early in the course to frank obtundation and coma as the syndrome progresses. This reflects both direct effects of central dopamine depletion and secondary metabolic derangements (acidosis, renal failure, hyperthermia).

The classic mnemonic for remembering the tetrad is "FARM": Fever, Autonomic instability, Rigidity, Mental status change.

It is critical to note that NMS can also occur when dopaminergic medications are abruptly withdrawn, such as sudden cessation of levodopa/carbidopa in a Parkinson disease patient. The mechanism is identical: a rapid drop in central dopamine activity.

02Clinical Manifestation

Symptoms develop over 24 to 72 hours after the causative drug is initiated, increased in dose, or (in the case of dopaminergic agents) abruptly discontinued. The syndrome typically lasts 7 to 14 days after the offending oral agent is stopped, but can persist for weeks if a long-acting depot formulation (e.g., fluphenazine decanoate) was used.

Mild cases may present with only low-grade fever and mild rigidity. Severe cases progress to temperatures above 41 C, rhabdomyolysis with CK levels exceeding 100,000, renal failure, and multiorgan dysfunction. The mortality rate without treatment historically ranges from 10% to 20%.

03Diagnostic Workup

NMS is a clinical diagnosis. There is no single confirmatory laboratory test or imaging study that establishes the diagnosis. The diagnostic process centers on recognizing the combination of characteristic clinical features in the appropriate pharmacological context and systematically excluding alternative explanations.

The best initial laboratory test is a serum CK level. An elevated CK in a patient with recent antipsychotic exposure, fever, rigidity, and altered mental status should immediately raise suspicion for NMS. CK levels correlate roughly with the severity of muscle injury and the risk of renal complications.

The workup proceeds with a complete blood count (which typically shows leukocytosis without left shift or bandemia, helping to differentiate from sepsis), a basic metabolic panel (to evaluate for acute kidney injury and hyperkalemia from rhabdomyolysis), and liver function tests (AST and ALT elevation reflects both hepatic injury and skeletal muscle breakdown).

Urinalysis classically shows a positive dipstick for blood in the absence of red blood cells on microscopy. This is because the dipstick reacts to the heme group in myoglobin, not just hemoglobin. This finding in the right clinical context strongly supports rhabdomyolysis.

Serum iron is a frequently tested ancillary marker. Low serum iron is found in the majority of NMS cases and can help differentiate NMS from other causes of hyperthermia with rigidity. However, it is not routinely used as a standalone diagnostic criterion.

Brain imaging (CT or MRI) and lumbar puncture are typically ordered not to confirm NMS but to rule out meningitis, encephalitis, or intracranial hemorrhage, which can present with fever, altered mental status, and rigidity. Results are normal in NMS. The CSF profile should be unremarkable; if pleocytosis or elevated protein is found, the clinician must pursue an infectious or autoimmune CNS etiology instead.

There is no gold-standard confirmatory test for NMS. The diagnosis rests on the clinical triad/tetrad in the setting of dopamine-blocking drug exposure, supported by laboratory evidence of muscle injury and systemic inflammation.

04Management & Treatment

Step 1: Discontinue the offending agent immediately. This is the single most important intervention and the correct "next best step" in any vignette presenting NMS. Every second of continued dopamine blockade worsens the syndrome. If the patient is on a depot antipsychotic, recognize that the drug effect will persist for weeks, necessitating more aggressive pharmacologic support.

Step 2: Aggressive supportive care. The patient requires ICU-level monitoring. IV crystalloid resuscitation should be initiated to maintain urine output above 200 mL/hr, which is essential to prevent myoglobin-induced acute tubular necrosis. Active cooling with ice packs to the axillae and groin, cooling blankets, and evaporative methods should be applied. Antipyretics (acetaminophen, NSAIDs) are generally ineffective because the hyperthermia is driven by muscular heat generation and hypothalamic dysregulation, not by prostaglandin-mediated fever. This distinction is a frequently tested concept.

Step 3: Dantrolene sodium. This is a direct-acting skeletal muscle relaxant that works by inhibiting calcium release from the sarcoplasmic reticulum via the ryanodine receptor. It directly addresses the sustained muscle contraction driving rhabdomyolysis and heat production. The dose is 1 to 2.5 mg/kg IV, repeated every 5 to 10 minutes as needed, up to a maximum cumulative dose of 10 mg/kg/day. Once the patient improves, oral dantrolene (25 to 100 mg every 6 hours) can be continued. Hepatotoxicity is the principal adverse effect of dantrolene and requires monitoring of liver function tests.

Step 4: Bromocriptine. This dopamine D2 agonist directly counteracts the central dopamine depletion that drives NMS. The initial dose is 2.5 mg orally or via nasogastric tube every 8 hours, titrated upward to a maximum of 45 mg/day based on clinical response. It should be continued for at least 10 days after clinical resolution, then tapered gradually to prevent rebound. Bromocriptine should not be abruptly discontinued, as this can trigger recurrence. An alternative dopamine agonist is amantadine (100 mg PO twice daily).

Step 5: Benzodiazepines (e.g., lorazepam 1 to 2 mg IV) serve as adjunctive therapy for agitation and may provide additional muscle relaxation through their GABAergic mechanism. They are not first-line but are useful for symptom control.

Step 6: Electroconvulsive therapy (ECT) is reserved for cases that are refractory to pharmacologic management, particularly when NMS overlaps with or transitions into lethal catatonia. ECT is effective because it modulates central dopaminergic and GABAergic neurotransmission.

Regarding recurrence prevention: If the patient requires ongoing antipsychotic therapy, rechallenge should be attempted only after a minimum 2-week drug-free interval. A low-potency or atypical antipsychotic (e.g., quetiapine) should be selected, initiated at the lowest effective dose, and uptitrated slowly with close clinical monitoring. The risk of recurrence upon rechallenge is estimated at 15% to 30%.

05Differential Diagnosis & Distractors

06Traps & High-Yield Pearls

The most common way students get NMS questions wrong is by confusing it with serotonin syndrome. Both conditions feature fever, altered mental status, and autonomic dysfunction after a medication change. The discriminating features are motor findings and drug class. NMS produces lead-pipe rigidity with bradyreflexia, while serotonin syndrome produces clonus and hyperreflexia. NMS follows exposure to dopamine antagonists (antipsychotics, metoclopramide, prochlorperazine) and develops over days, while serotonin syndrome follows serotonergic agents and develops within hours. If a vignette mentions clonus or diarrhea, it is almost always pointing you toward serotonin syndrome, not NMS.

A second common trap is failing to recognize that metoclopramide and prochlorperazine are dopamine antagonists. Students associate NMS exclusively with psychiatric medications and miss the diagnosis when the offending drug is an antiemetic given in a surgical or obstetric setting. Any D2 antagonist can trigger NMS.

A third tested concept is the recognition that antipyretics do not work in NMS. Because the hyperthermia is generated by sustained muscular contraction and hypothalamic failure rather than prostaglandin-mediated pyrogen activity, acetaminophen and ibuprofen are ineffective. The correct cooling strategy involves physical methods and dantrolene.

Finally, be alert for vignettes describing a Parkinson disease patient whose levodopa was abruptly discontinued and who then develops fever, rigidity, and altered mental status. This is NMS by mechanism (acute dopamine depletion), and the treatment is the same: supportive care, dantrolene, and restoration of dopaminergic therapy (restart levodopa). Students who do not recognize this variant will incorrectly attribute the presentation to infection or disease progression.

The core competency being tested is pattern recognition: identifying the pharmacological trigger, linking the clinical tetrad (Fever, Autonomic instability, Rigidity, Mental status change) to central dopamine depletion, ordering the correct labs (CK as the best initial test), and choosing the correct management sequence (stop drug first, then dantrolene and bromocriptine).